Measuring the states of cell signaling pathways in tumor samples promises to advance the understanding of oncogenesis and identify response biomarkers. Here, we describe the use of Reverse Phase Protein Arrays (RPPAs or RPLAs) to profile signaling proteins in 56 breast cancers and matched normal tissue. In RPPAs, hundreds to thousands of lysates are arrayed in dense regular grids and each grid is probed with a different antibody (100 in the current work, of which 71 yielded strong signals with breast tissue). Although RPPA technology is quite widely used, measuring changes in phosphorylation reflective of protein activation remains challenging. Using repeat deposition and well-validated antibodies, we show that diverse patterns of phosphorylation can be monitored in tumor samples and changes mapped onto signaling networks in a coherent fashion. The patterns are consistent with biomarker-based classification of breast cancers and known mechanisms of oncogenesis. We explore in detail one tumor-associated pattern that involves changes in the abundance of the Axl receptor tyrosine kinase (RTK) and phosphorylation of the cMet RTK. Both cMet and Axl have been implicated in breast cancer, or in resistance to anticancer drugs, but the two RTKs are not known to be linked functionally. Protein depletion and overexpression studies in a 'triple-negative' breast cell line reveal cross talk between Axl and cMet involving Axl-mediated modification of cMet, a requirement for cMet in efficient and timely signal transduction by the Axl ligand Gas6 and the potential for the two receptors to interact physically. These findings have potential therapeutic implications, as they imply that bi-specific receptor inhibitors (for example, ATP-competitive small-kinase inhibitors such as GSK1363089, BMS-777607 or MP470) may be more efficacious than the mono-specific therapeutic antibodies currently in development (for example, Onartuzumab).
Oncogenic selection functions at the level of networks and pathways rather than individual genes. 1 To date, most multiplex analyses of clinical specimens have involved genomic data because measurement of gene sequences and expression levels is reliable and relatively simple. However, expression profiling does not report directly on regulation at the level of protein abundance or post-translational modification, both of which are required to understand the activities of signaling pathways. 2 Protein state can be assayed using conventional immunoblotting, but this technique has relatively low throughput. The throughput of mass spectrometry (LC/MS) is much greater in terms of total number of data-points but relatively large samples are required, a problem when working with clinical specimens, and assaying many samples remains slow. In the past few years, 'Reverse-phase' protein microarrays (RPPAs) have emerged as a way to perform high-throughput immune-based assays on small amounts of material. In an RPPA, thousands of lysates are arrayed in a dense, regular grid onto glass-supported nitrocellulose pads mounted on a microscope slide, which is then probed with a different antibody. [3] [4] [5] [6] [7] [8] Subsequent visualization of the bound antibody on each spot provides a quantitative measure of specific antigens in immobilized samples. A drawback of this approach is that only a small subset of antibodies are sufficiently selective to work in an RPPA format 9 largely, because off-target binding by antibodies contributes to the overall signal. Nonetheless, several studies have shown that RPPA technology is effective in mapping intracellular signaling networks in cell lines. 3, [10] [11] [12] [13] Here, we ask whether RPPAs can also be used to analyze phosphorylationmediated signal transduction in human tumor samples.
The current study is a collaboration between a company specializing in rapid processing of surgical tissues and an academic group experienced in RPPA analysis (samples of the lysates analyzed in this paper are available from www. proteinbiotechnologies.com for those who wish to follow up our experiments). Analyzing post-translational modifications in clinical samples require that biopsies be processed rapidly to minimize degradation and dephosphorylation: tissue ischemia alters the expression of 10-15% of all genes within 15 min of resection, and B30% of all proteins change in abundance within 30 min.
14 To minimize the changes in protein abundance and phosphorylation, tumors were flash-frozen in liquid nitrogen within 5-10 min of resection. Adjacent normal tissue was also collected and processed in parallel. Frozen tissue was minced and homogenized in cold modified RIPA buffer and total protein levels were quantified (Bio-Rad Laboratories). Tumors included the major histotypes and stages of breast cancer: most cases (n ¼ 48) were classified as ductal carcinoma of varying grade; mucinous and intraductal cancers were represented by three samples each; and lobular and a metaplastic tumors by one sample (Supplementary Table S1 ).
Approximately 100 arrays were printed from normal and tumorderived extracts (B10 mg total protein per extract), with each array receiving eight depositions per spot to increase the signal-to-noise ratio. Arrays were adhered to bottomless microtiter plates, allowing rapid processing of 100 arrays with 100 different primary antibodies (Figure 1a ). Slides were incubated with dye-labeled secondary antibodies and scanned to quantify fluorescence levels on a spot-by-spot basis. Primary antibodies were directed against proteins, or phosphorylated forms of proteins, known to have a role in oncogenic signal transduction. Several thousand antibodies have been screened by us and by others 8, 9 to identify the B5% of commercial antibodies that exhibit sufficient specificity in multiple cell lines (Figure 1b) , particularly for the phosphorylated forms of receptor tyrosine kinases (RTKs), and the cytosolic and nuclear proteins they regulate (Figure 1c over 400 commercial antibodies and successfully validated 100 of them in one or more biological context. 15, 16 Our RPPA antibody panel overlaps, but is not identical to, panels developed by investigators at MD Anderson Cancer Center, who are active in the Cancer Genome Atlas project 8, 9 ( Figure 1b ). With breast cancer samples, 71 members our 100-antibody panel yielded signals above background and were used in the current work to generate a set of B8,000 intensity measurements, each of which was performed in duplicate ( Figure 1c,d) . We estimate the technical error in the measurements to be B ± 5% (see Supplementary Materials for details). Normalizing the activity of specific measurements to total protein or to a panel of housekeeping proteins has been proven to be effective approaches and we applied the former. [17] [18] [19] The activities of phospho-antibodies ;were normalized either to total-protein levels or pan-specific antibodies against the same protein (for example, phospho-and total-FGFR receptor) when the reagents were available. RPPA data were standardized by dividing intensity values for each set of duplicate spots by the maximum intensity value for that particular antibody across all normal and cancer samples, thereby generating a set of 'activity ratios.' In general, distributions of activity ratios were narrower for normal tissue than for tumor tissue (Figure 2a ). For measurements such as the total levels of the Her2/ErbB2 receptor (antibody ID 33), the distribution was unimodal for normal tissue and multimodal for tumor tissue (Figure 2a ). 'Fold-difference' is a robust metric for scoring the abundance or activities of signaling proteins, 20, 21 and we therefore calculated fold-change data by dividing activity ratios for tumor samples by ratios for matched normal tissue on an antibody-by-antibody basis. When data were ranked by the frequency of 41.5-fold difference, we observed significant changes between matched normal and tumor tissue for 54 out of 71 protein signals (Po0.05, Kolmogorov-Smirnov test (KS test); Figure 2b ). For example, keratin (protein ID:38) was overexpressed in tumor tissue in 55/56 patients (98%), whereas TCF1 (protein ID:20) was overexpressed in 20/56 patients (36%) (see Supplementary Table S2 for ID assignments). Protein biomarkers used to classify breast cancers clinically were elevated to a similar extent in RPPA data and in breast cancers in general: HER2/neu2 levels (which are predictive of responsiveness to trastuzumab 22 were elevated in 24/56 samples (43%) as compared with B30% of patients, based on the literature. 23 Similarly, estrogen or progesterone receptor levels, which are predictive of responsiveness to anti-hormonal therapy, were elevated in 22/56 (40%) of samples compared with B60% of patients. 24 Twelve out of fifty-six (21%) samples appeared to derive from triple-negative tumors, as compared with B20% of patients overall. Thus, RPPA data captures significant variation between tumor and normal tissue, and among different tumors, consistent with current understanding of breast cancer as a complex disease involving multiple subtypes.
As a first step in uncovering patterns of protein co-regulation, we performed unsupervised hierarchical clustering 25 and then drew a threshold in the dendrogram to highlight 12 clusters (that is, with an average cluster size of six specimens; Figure 3a) . Diagnostic biomarkers were observed to fall into distinct groups: HER2/neu co-clustered in group II with pro-survival signaling molecules such as pAkt1, pPI3K, pRSK3, pGSK3b, PDGFRb and insulin receptor; progesterone receptor co-clustered in group X with Vav1, peIF4G, pPLA2; and ER clustered by itself (group XI). It has been shown that mapping clusters of co-expressed genes onto pathways increases information content and intepretability. [26] [27] [28] [29] [30] We therefore mapped RPPA clusters onto pathways derived from Gene Network Central Pro (GNCPro); an online resource of literature-curated interaction graphs derived from protein-protein interaction and gene co-expression data. 31 In general, co-clustering RPPA measurements mapped onto known RTK signaling networks. For example, the cluster containing phosphorylated EGF receptor (pY845, group I) also contained the phosphorylated forms of kinases known to function downstream of epidermal growth factor receptor (EGFR) such as Raf1-pS289/ 296/301, S6K-pS235/236, CAM1-pS81 and PKC-pS660 (Figure 3b ). Phosphorylated forms of ERK (pT202/pY204), MEK (pS217/pS221) and S6K (pS240/pS244) kinases made up group VIII, consistent with the known topology of the MAPK signaling cascade and its importance in breast cancer 32 (Supplementary Figure S1) . We focused follow-up analysis on the cluster containing the RTK cMet (whose ligand is hepatocyte growth factor (HGF)): cMet levels are not currently used as a prognostic biomarker in breast cancer patients, but overexpression of the receptor is associated with poor clinical outcome, independent of HER2/neu status, 33 Studying cell signaling in breast tumor samples TS Gujral et al development. 34 We observed that levels of active cMet-pY1349 (group VII) clustered away from total HER2, ER and PR, and from pEGFR (pY845, and pY1173), but correlated well with the total level of the Axl receptor (R 2 ¼ 0.870, Po0.0001) and the phosphorylated form of the Stat3 transcription factor (R 2 ¼ 0.883, Po0.0001), generating a well-connected GNCPro network that also contained the phospho forms of the Gab1 adapter (pY627), kinases such as Pak1 (pS199/pS204) and GSK3b (pS21/pS9) and the transcription factor cJun (pT91/pT93). Total levels of Tcf1 also fell in this group. Axl is a member of the TAM (Tyro-Axl-Mer) family of receptor tyrosine kinases and has previously been shown to have a role in the motility and invasiveness of breast cancer cells. 35, 36 Large-scale network reconstruction suggests an interaction between cMet and Axl 37,38 and the two receptors are co-regulated by miR-34a in breast cancer cell lines. 39 As a statistically rigorous way to investigate possible co-regulation of Axl and cMet in RPPA data, we turned to structured Bayesian inference involving 11 assays for proteins known to be involved in cMet and Axl signal transduction (10 phospho-proteins and 1 total protein, most of which clustered in group 7). We considered 15 network topologies, all of which involved the class random variable cancer versus normal. The performance of these models was compared to that of four networks in which the cMet and Axl receptors were presumed to covary with cannonical downstream effectors such as Raf and Akt. To learn the parameters of the Bayesian networks, data on RPPA activity ratios were discretized (Supplementary Text and Figure S2 ) and inference performed on a training-and test-set. The greatest generalization accuracy (82%) was acheived with a network containing the interactions pcMet-Axl, pcMet-pRaf and pRafpAkt; adding more interactions decreased the quality of the inference, showing that simpler networks captured all of the available data. Covariation captured by Bayesian inference is not evident from simple inspection of individual probability distributions for p-cMet and total Axl (Figure 2a ): p-cMet levels are unimodal and nearly identical in normal and tumor samples, whereas total Axl levels are bimodally distributed in tumor samples (and have a higher mean value; Po0.05, KS-test; Figure 2b ). Bayesian network analysis captures the fact that higher p-cMet levels correlate with higher levels of total Axl and this covariation also correlates with the activation of Raf and Akt (Figure 4a, Supplementary Figure S2) . Protein-interaction networks were constructed for each of these clusters using the GNCPro tool. The proteins measured in this study that clustered together are highlighted in green. Red circle denotes phosphorylation measurement. First neighbors of selected proteins are shown in white. Proteins that were measured but do not fall within the cluster are highlighted in orange. Three receptor tyrosine kinases involved in breast cancer, EGFR, Her2 and cMet, form three distinct clusters. The EGFR network cluster (cluster I) includes pPLCg, pPKC, ITK, pRAF, pS6 and pCAMI kinases. The data show that the phosphorylation of cMet kinase correlated with phosphorylation of its downstream substrates, Gab1 and Stat3, consistent with established network topology of cMet signaling (cluster VII). [52] [53] [54] [55] Phosphorylation of cMet also correlated with phosphorylation of c-Jun and protein levels of Tcf1. In addition to these known components of cMet pathway, measurements for the phosphorylation p21-activated kinase (Pak1) and total levels of Axl fell in the same cluster.
To determine if cMet and Axl receptors interact functionally, we turned to breast cancer cell that express both receptors. Exposing MDA-MB-231 triple-negative breast cancer cells to the Axl ligand Gas6 (growth arrest-specific 6) activated multiple downstream signaling cascades, including the PI3K-Akt, MAP kinase, NF-kB and JAK-STAT pathways. 40 Exposing these cells to cMet HGF activated many of the same signaling molecules. To determine if Gas6-and HGF-mediated signaling are interdependent at the receptor level, MDA-MB-231 cells were exposed to either Gas6 or HGF, and Axl and cMet receptor phosphorylation assayed by ELISA. We observed that Gas6 caused transient phosphorylation of Axl, peaking at 15 min and falling to baseline levels by 60 min (Figure 4b) . No increase in phospho-cMet levels were observed. In contrast, exposure of cells to HGF resulted in transient phosphorylation of both cMet and Axl receptors: p-cMet peaked at 15 min and p-Axl peaked at 30 min (Figure 4b ). This suggests cross talk between the two receptors, as has previously been demonstrated for cMet and EGFR in lung tumor cells that have acquired resistance to the EGFR inhibitors gefitinib or between IGF1 recepor and EGFR in breast cancers resistant to erlotinib. 41, 42 To investigate the consequences of Axl and cMet interaction on downstream signaling, we used xMAP micro-sandwich assays 43 to measure the phosphorylation status of 19 signaling proteins at 4-5 time points ranging from 0 to 120 min after exposure of MDA-MB-231 cells to HGF or Gas6 (Figure 4c, Supplementary Figure S3 ). Both ligands activated Akt (pS473), CREB (pS133), GSK3a/b (pS21/ pS9), Erk1 (pT202/pY204), c-Jun (pS63), MEK1 (pS217/pS221), S6 (pT421/pS424) and Stat3 (pS727), but NFkB phosphorylation (pS536) was observed only after Gas6 exposure, as previously described. 44 We then used RNAi to deplete cells of one receptor or the other, and exposed them to Gas6 or HGF. Axl mRNA and protein levels were depleted B10-fold (Figure 4d, Supplementary  Figure S4 ), and we observed 5-10-fold reductions in Gas6-induced phosphorylation of downstream proteins. Knocking down cMet by RNAi was less efficient (four-fold depletion at the mRNA level and overexpressed Axl and cMet can be co-precipitated (blue line) and the two receptors are transcriptionally co-regulated. 56 The dashes are intended to convey the idea that interactions might be indirect.
two-fold at the protein level, Figure 4d, Supplementary Figure S4) , resulting in a 2-4-fold reduction and a delay in both HGF and Gas6-mediated phosphorylation of downstream proteins (Figure 4c,  Supplementary Figure S3 ). Knocking down cMet also resulted in a reduction in Axl mRNA levels, consistent with previous reports that the two receptors are co-regulated and consistent with delays in Gas6-mediated phosphorylation of downstream signaling proteins (Figure 4d ). The converse was not true, however, Axl depletion did not alter the dynamics or magnitude of HGF-mediated signal transduction. Several studies have shown that knockdown of Met or Axl reduced motility, invasiveness and tumorogenicity in mice. [45] [46] [47] [48] In our hands, dual knockdown of Axl and cMet in MDA-MB-231 cells also increased cell death. (Figure 4e ) and knockdown of either gene reduced cell migration in a wound-healing assay (Supplementary Figure S5) . Thus, both Axl and cMet are involved in typical oncogenic processes in MDA-MB-231 and they may act cooperatively in pro-survival signaling. Co-immunoprecipitation of ectopically expressed Axl and cMet also suggested that the receptors may associate physically: we detected the presence of myc-cMet in HA-Axl immuno-precipitates prepared from lysates of HEK 293 cells overexpressing HA-tagged Axl and myc-tagged cMet (Supplementary Figure S6) . Co-purification has been observed in some but not all previously described heterotypic RTK interactions: for example, IGF1R and EGFR, but not cMet and EGFR, co-purify in drug-resistant cell lines. 49 The details of the interaction between cMet and Axl remain to be elucidated and are likely to be complex: although HGF exposure causes both cMet and Axl phosphorylation, knocking down Axl does not appear to alter HGF-mediated phosphorylation of downstream proteins. In contrast, Gas6 exposure results only in Axl phosphorylation, but knocking down cMet alters the timing and magnitude of Gas6-mediated signaling (Figure 4f ). Despite these complexities, cell line data support the findings from RPPA analysis showing that Axl and cMet receptors exhibit cross talk and may interact physically in breast cancer cells.
In this paper, we show that RPPA analysis can be used to assay the activation state of signaling proteins in lysates derived from primary tumors. Patterns of protein phosphorylation are remarkably diverse from one tumor to the next, but are consistent with the known topologies of oncogenic signaling pathways and with biomarker-based classification of breast cancer subtypes. The current study benefits from the availability of high-quality lysates, but suffers from a lack of access to genomic data or the clinical histories of the individual patients. We have therefore focused on pathway inference, specifically with regard to the cMet and Axl RTKs. It is highly probable that additional information can be extracted from our RPPA data using more sophisticated analytical methods, and we encourage others to download the data.
If cMet and Axl function coordinately in cancer, as we hypothesize, then it may be advantageous to develop bi-specific antibodies that block both receptors simultaneously. Therapeutic antibodies currently in development that target cMet, such as Onartuzumab are not expected to block Axl, but small molecule cMet kinase inhibitors (GSK1363089, BMS-777607, MP470) do appear to inhibit Axl as well. 34, 50, 51 More generally, positive results from the current study provide an impetus to clinical investigators, drug companies and institutional review boards to include phosphorylation-rich RPPA analysis in the analysis of clinical data. We note that relatively little work will be required to create a superset of 133 well-validated antibodies spanning both the HMS and MD Anderson RPPA platforms.
